GlassScriptPhysician profile
Darryl A Hamilton
NPI 1972537397
$3,517.12
in general payments reported to CMS, 2019-2025
28 companies · $442 in 2025
The $442 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $232 · 2021: $463 · 2022: $685 · 2023: $488 · 2024: $546 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,476.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $505.48 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $411.05 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $405.73 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $330.88 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $316.76 | 2019-2025 | Lifevest |
| Pfizer INC. | $221.31 | 2019-2025 | |
| Amgen INC. | $194.92 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $120.50 | 2020-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Abbott Laboratories | $118.62 | 2022-2024 | Gallant, Cardiomems |
| Medtronic, INC. | $96.38 | 2023-2024 | Avalus, Linq II, Tyrx |
| Astrazeneca Pharmaceuticals LP | $91.53 | 2019-2023 | Enhertu |
| Lexicon Pharmaceuticals, INC. | $87.46 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.50 | 2021-2025 | Jardiance |
| Braemar Manufacturing, LLC | $73.99 | 2019 | |
| Novo Nordisk INC | $70.51 | 2024-2025 | Ozempic, Rybelsus |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $66.71 | 2022-2023 | Iclusig |
| Eisai INC. | $66.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $45.27 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $38.24 | 2019 | |
| Medtronic Vascular, INC. | $32.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.52 | 2025 | |
| Biosense Webster, INC. | $21.19 | 2023 | Carto 3 |
| Kiniksa Pharmaceuticals International, Plc | $20.22 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $18.96 | 2024 | Zio Xt Patch, Zio Monitor |
| Amarin Pharma, INC. | $17.70 | 2022 | |
| Boston Scientific Corporation | $15.94 | 2023 | Watchman Access System |
| Esperion Therapeutics, INC. | $12.46 | 2021 | |
| Celonova Biosciences, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.